Garrido and colleagues have proposed that tumor MHC-I downregulation or loss is categorized as “soft” and “hard” alterations, depending on whether the loss of MHC-I expression is reversible (such as transcriptional downregulation) or not (for instance, loss of both copies of a gene such as B2M) [50,206]. This evidence concerns the gene B2M and neoplasm.